sb 239063 has been researched along with Obesity in 1 studies
SB 239063: structure in first source
SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pereira, S | 1 |
| Yu, WQ | 1 |
| Moore, J | 1 |
| Mori, Y | 1 |
| Tsiani, E | 1 |
| Giacca, A | 1 |
1 other study available for sb 239063 and Obesity
| Article | Year |
|---|---|
Effect of a p38 MAPK inhibitor on FFA-induced hepatic insulin resistance in vivo.
Topics: Activating Transcription Factor 2; Animals; Blood Glucose; Emulsions; Enzyme Inhibitors; Fatty Acids | 2016 |